Neopterin - Kurzinfos Neopterin - Deutsch Neopterin - English
Measurement Biological Effects Oxidative Stress HIV-Infection Trauma, Sepsis Cancer Autoimmunity Heart Diseases Immunmodulation Blood Tranfusion In Vitro Testing Anemia Tryptophan Degradation Homocysteine Soluble TNF-Receptor Infection
Winterworkshop 2008 Winterworkshop 2007 Winterworkshop 2006 Winterworkshop 2005 Winterworkshop 2004 Awards
View the Crew Neopterin Treff Alpine Surroundings Most Recent Salfeins Paintings
Chemisches Rechnen AIDS aktuell Neopterin Clinical Biochemistry of Infectious Diseases
Impressum Scientific References Curriculum Impact Factor

Increased neopterin concentrations are common in patients suffering from malignant tumors. Neopterin concentrations correlate with stage of the disease and provide significant predictive information for the disease development.


Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies

 Melichar B, et al. Departments of Oncology & Radiotherapy, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic

(Int J Gynecol Cancer 2006;16:240-52.)

 Malignant tumors may contribute to host response that involves both the adaptive and innate immune systems. Among other biochemical indicators of systemic immune and inflammatory activity, activation of macrophages by interferon-gamma induces a marked increase in the production of neopterin. Neopterin production by activated macrophages is also associated with tryptophan degradation. In addition to tumors of other primary locations, increased urinary and serum neopterin concentrations have been reported in patients with gynecological cancers, including epithelial ovarian carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcomas, and vulvar carcinoma, but not in women with benign neoplasms or precancerous disorders. Increased neopterin concentrations have been associated with poor prognosis. Elevated levels of neopterin have also been observed in the tumor microenvironment. Systemic (urinary or serum) or local (ascitic fluid) neopterin concentrations increased after therapeutic administration of cytokines. Elevated neopterin concentrations have been associated with anemia of chronic disease and increased urinary zinc loss in patients with gynecological malignancy. Elevated neopterin has also been connected with depressed function of peripheral blood lymphocytes and a decrease in CD4+ T-cell numbers.

 Neopterin as a marker for activated cell-mediated immunity: application in malignant disease.

Reibnegger G, et al. Institute for Medical Chemistry and Biochemistry, University of Innsbruck, Austria
(Cancer Detect Prev 1991; 15: 483-90)

 A review is presented on studies concerning neopterin determination in patients with malignant neoplastic diseases. Neopterin is produced chiefly by human macrophages through their activation by T-cell-derived interferon gamma. In vivo, determination of neopterin in various body fluids provides a convenient way to monitor early events that are involved in cell-mediated immune responses. In malignant neoplasia, elevation of neopterin concentrations in body fluids depends on tumor type. Within a given type of tumor, more advanced stages are generally associated with higher levels than early disease. In a variety of different tumor types and sites, a significantly poorer prognosis was associated with high pretherapeutic neopterin concentrations. This predictive value is independent of several possible confounders such as stage or therapy. During follow-up malignant disease, neopterin elevations may predict deterioration of the clinical status of the patients and thereby provide a valuable additional marker for monitoring such patients. Possible immunobiological implications of the results are discussed.

 Increased urinary excretion of neopterin in patients with malignant tumors and with virus diseases 

 Wachter H, et al. Institute for Medical Chemistry and Biochemistry, University of Innsbruck, Austria
(Hoppe Seylers Z Physiol Chem 1979; 360: 1957-60)

Heightened urinary concentrations of neopterin were detected in patients with malignant tumors. The levels of neopterin were quantified by high performance liquid chromatography. The normal range for male individuals was 280 +/- 1,7 ng neopterin/mg creatinine, for women 340 +/- 116 ng neopterin/mg creatinine. The values found in patients with malignant tumors were 1370 +/- 495 ng neopterin/mg creatinine and in patients with virus diseases 1637 +/- 696 ng neopterin/mg creatinine.

Text is also avaialble in Polish language (, translated by Valeria Aleksandrova.